000147629 001__ 147629
000147629 005__ 20240229112653.0
000147629 0247_ $$2doi$$a10.1017/S2045796019000702
000147629 0247_ $$2pmid$$apmid:31722770
000147629 0247_ $$2ISSN$$a1121-189X
000147629 0247_ $$2ISSN$$a2038-1816
000147629 0247_ $$2ISSN$$a2045-7960
000147629 0247_ $$2ISSN$$a2045-7979
000147629 0247_ $$2altmetric$$aaltmetric:70447221
000147629 037__ $$aDKFZ-2019-02620
000147629 041__ $$aeng
000147629 082__ $$a610
000147629 1001_ $$0P:(DE-He78)6cc3cc35505b446fde081e7cd89a4b87$$aMöllers, Tobias$$b0$$eFirst author$$udkfz
000147629 245__ $$aAlzheimer's disease medication and outcomes of hospitalisation among patients with dementia.
000147629 260__ $$aCambridge$$bCambridge Univ. Press$$c2019
000147629 3367_ $$2DRIVER$$aarticle
000147629 3367_ $$2DataCite$$aOutput Types/Journal article
000147629 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1583743323_7398
000147629 3367_ $$2BibTeX$$aARTICLE
000147629 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000147629 3367_ $$00$$2EndNote$$aJournal Article
000147629 500__ $$a2019 Nov 14;29:e73seit 2013 erscheint die Zeitschrift nur noch online
000147629 520__ $$aThe use of Alzheimer disease medication for the treatment of dementia symptoms has shown significant benefits with regards to functional and cognitive outcomes as well as nursing home placement (NHP) and mortality. Hospitalisations in these patient groups are characterised by extended length of stays (LOS), frequent readmissions, frequent NHP and high-mortality rates. The impact of Alzheimer disease medication on the aforementioned outcomes remains still unknown. This study assessed the association of Alzheimer disease medication with outcomes of hospitalisation among patients with Alzheimer disease and other forms of dementia.A dynamic retrospective cohort study from 2004 to 2015 was conducted which claims data from a German health insurance company. People with dementia (PWD) were identified using ICD-10 codes and diagnostic measures. The main predictor of interest was the use of Alzheimer disease medication. Hospitalisation outcomes included LOS, readmissions, NHP and mortality during and after hospitalisation across four hospitalisations. Confounding was addressed using a propensity score throughout all analyses.A total of 1380 users of Alzheimer disease medication and 6730 non-users were identified. The use of Alzheimer disease medication was associated with significantly shorter LOS during the first hospitalisations with estimates for the second, third and fourth showed a tendency towards shorter hospital stays. In addition, current users of Alzheimer disease medication had a lower risk of hospital readmission after the first two hospitalisations. These associations were not significant for the third and fourth hospitalisations. Post-hospitalisation NHP and mortality rates also tended to be lower among current users than among non-users but differences did not reach statistical significance.Our results indicate that Alzheimer disease medication might contribute to a reduction of the LOS and the number of readmissions in PWD.
000147629 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000147629 588__ $$aDataset connected to CrossRef, PubMed,
000147629 7001_ $$0P:(DE-He78)d9d72431035d8535d1b65ce9a01c2f60$$aPerna, L.$$b1$$udkfz
000147629 7001_ $$0P:(DE-He78)f0a01df447f74d4e57b596d985130a15$$aStöcker, Sarah$$b2
000147629 7001_ $$aIhle, P.$$b3
000147629 7001_ $$aSchubert, I.$$b4
000147629 7001_ $$0P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aSchöttker, B.$$b5$$udkfz
000147629 7001_ $$aFrölich, L.$$b6
000147629 7001_ $$aBauer, J.$$b7
000147629 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b8$$eLast author$$udkfz
000147629 773__ $$0PERI:(DE-600)2594528-2$$a10.1017/S2045796019000702$$gp. 1 - 9$$pe73$$tEpidemiology and psychiatric sciences$$v29$$x2045-7979$$y2019
000147629 909CO $$ooai:inrepo02.dkfz.de:147629$$pVDB
000147629 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6cc3cc35505b446fde081e7cd89a4b87$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000147629 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d9d72431035d8535d1b65ce9a01c2f60$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000147629 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000147629 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000147629 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000147629 9141_ $$y2019
000147629 915__ $$0StatID:(DE-HGF)0400$$2StatID$$aAllianz-Lizenz / DFG
000147629 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000147629 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEPIDEMIOL PSYCH SCI : 2017
000147629 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000147629 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000147629 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000147629 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000147629 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000147629 915__ $$0StatID:(DE-HGF)0130$$2StatID$$aDBCoverage$$bSocial Sciences Citation Index
000147629 915__ $$0StatID:(DE-HGF)1180$$2StatID$$aDBCoverage$$bCurrent Contents - Social and Behavioral Sciences
000147629 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000147629 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEPIDEMIOL PSYCH SCI : 2017
000147629 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000147629 980__ $$ajournal
000147629 980__ $$aVDB
000147629 980__ $$aI:(DE-He78)C070-20160331
000147629 980__ $$aUNRESTRICTED